[Oncogene] Transcriptomic analysis of the LNCaP prostate cancer cell line shows a significant overlap in genes regulated by FUS and the androgen receptor

[Scientific Reports] Researchers evaluated the impact of miR-340-mediated downregulation of MDM2 on the therapeutic efficacy of p53 gene therapy in p53 non-expressing PC3 cells.

[Cell Death Discovery] Investigators conducted gain- and loss-of-function studies in prostate cancer cell lines and mouse subcutaneous xenograft models to elucidate the role of Neurexophilin 4 (NXPH4) in CRPC.

[Nature Reviews Clinical Oncology] Scientists discuss the personalized management of both non-metastatic and metastatic hormone-sensitive prostate cancer, including how to select patients for docetaxel, choice of androgen receptor pathway inhibitors and use of radiotherapy to primary and metastatic disease sites.

[Journal of Molecular Medicine] The authors summarize the multifaceted regulation of ferroptosis in prostate cancer from molecular, metabolic, and microenvironmental perspectives.

[Cancer Discovery] Scientists established a novel analysis pipeline, Spot Neoantigens in Metastases, that systematically identifies treatment resistance mutations and their predicted derived neoantigens.

[Pfizer] Pfizer announced the recipients of a series of grants to help advance oncology research. An investment of $900,000 has been made across different projects to support the development of patient-centric solutions for some of Canada’s most diagnosed cancers: lung, colorectal, prostate, and bladder cancer.

[K36 Therapeutics (BioSpace)] K36 Therapeutics, Inc. announced completion of dosing in the first patient cohort of its Phase I clinical trial evaluating KTX-2001, a first-in-class, orally administered, selective NSD2 inhibitor, in patients with metastatic CRPC.

[Mbio] Researchers performed RNA sequencing and transcription factor network analyses of primary CD4+ T cells infected with HIV-1 harboring an intact or defective vpr open reading frame.

[Signal Transduction and Targeted Therapy] The authors discuss the classification of oncolytic viruses and their multimodal mechanisms that target tumorigenesis, metastasis, disease recurrence, and therapy resistance.

[Nature Communications] Scientists reported the establishment of NEO-STIM, an ex vivo induction process to prime and expand pre-existing memory and de novo CD8+ and CD4+ T cell responses, thereby highlighting critical parameters for generating potent neoantigen-specific T cell responses.

[Molecular Therapy] Researchers used their HLA-A*02 CAR and immunosuppressive IL-10 as model components to generate human CAR-Tregs that release IL-10 upon CAR-engagement.